Premium
Clinical outcomes in elderly patients with human papillomavirus–positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy
Author(s) -
Hanasoge Sheela,
Magliocca Kelly R.,
Switchenko Jeffrey M.,
Saba Nabil F.,
Wadsworth J. Trad,
ElDeiry Mark W.,
Shin Dong M.,
Khuri Fadlo,
Beitler Jonathan J.,
Higgins Kristin A.
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24073
Subject(s) - medicine , human papillomavirus , radiation therapy , toxicity , head and neck squamous cell carcinoma , basal cell , oncology , overall survival , chemoradiotherapy , retrospective cohort study , head and neck cancer , chemotherapy , head and neck , surgery
Background The benefit of combined chemoradiation in elderly patients with human papillomavirus (HPV)‐positive locally advanced oropharyngeal squamous cell carcinoma (SCC) must be balanced with the potential for higher toxicity rates. We performed a retrospective review of our institutional experience. Methods Patients 70 years or older with p16‐positive oropharyngeal SCC treated with definitive chemoradiation from 2005 to 2013 were evaluated. Overall survival (OS), disease‐free survival (DFS), and locoregional failure–free survival were calculated. Results Twenty‐one eligible patients had a follow‐up of 22.4 months. Estimated 5‐year OS, DFS, and locoregional failure–free survival were 76.0%, 40%, and 95%, respectively. There was 1 death from acute toxicity, and 50% had unplanned hospitalizations. Sixty percent had late toxicity, and 6‐month feeding tube dependence was 25%. Conclusion Elderly patients with HPV‐positive locally advanced SCC of the oropharynx treated with definitive chemoradiation had good OS but high rates of acute and long‐term toxicity. © 2015 Wiley Periodicals, Inc. Head Neck 38: 846–851, 2015